To include your compound in the COVID-19 Resource Center, submit it here.

First-line pancreatic cancer readout sinks Halozyme shares

Halozyme Therapeutics Inc. (NASDAQ:HALO) slipped $1.76 to $17.98 Wednesday after reporting that PEGPH20 plus modified FOLFIRINOX chemotherapy led to worse overall survival (OS) compared

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE